tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

APGN

Pyxis Oncology successfully completes acquisition of Apexigen
The FlyPyxis Oncology successfully completes acquisition of Apexigen
1y ago
APGN
PYXS
Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
PremiumPress Releases
Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
1y ago
APGN
Apexigen Soars on Acquisition by Pyxis Oncology
PremiumMarket News
Apexigen Soars on Acquisition by Pyxis Oncology
1y ago
APGN
PYXS
Roth MKM biotech analysts to hold analyst/industry conference call
PremiumThe Fly
Roth MKM biotech analysts to hold analyst/industry conference call
1y ago
APGN
RAIN
Roth MKM biotech analysts to hold analyst/industry conference call
PremiumThe Fly
Roth MKM biotech analysts to hold analyst/industry conference call
1y ago
APGN
RAIN
Roth MKM biotech analysts to hold analyst/industry conference call
PremiumThe FlyRoth MKM biotech analysts to hold analyst/industry conference call
2y ago
APGN
RAIN
Apexigen downgraded to Hold from Buy at Brookline
Premium
The Fly
Apexigen downgraded to Hold from Buy at Brookline
2y ago
APGN
Apexigen downgraded to Neutral from Buy at Roth MKM
Premium
The Fly
Apexigen downgraded to Neutral from Buy at Roth MKM
2y ago
APGN
Apexigen announces review of strategic alternatives, 55% workforce reduction
PremiumThe Fly
Apexigen announces review of strategic alternatives, 55% workforce reduction
2y ago
APGN
Apexigen Announces Approximately $2.8 Million Private Placement Financing
PremiumPress Releases
Apexigen Announces Approximately $2.8 Million Private Placement Financing
2y ago
APGN
Apexigen announces $2.8M private placement financing
PremiumThe Fly
Apexigen announces $2.8M private placement financing
2y ago
APGN
Apexigen resumed with a Buy at Roth Capital
PremiumThe Fly
Apexigen resumed with a Buy at Roth Capital
2y ago
APGN
Another Setback for Cancer as APGN Surges
PremiumMarket NewsAnother Setback for Cancer as APGN Surges
2y ago
APGN
Apexigen announces new data evaluating agonist antibody sotigalimab for CD40
Premium
The Fly
Apexigen announces new data evaluating agonist antibody sotigalimab for CD40
2y ago
APGN
Apexigen initiated with a Buy at EF Hutton
Premium
The Fly
Apexigen initiated with a Buy at EF Hutton
2y ago
APGN
Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update
PremiumPress Releases
Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update
2y ago
APGN
Apexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting
PremiumPress Releases
Apexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting
2y ago
APGN
Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
PremiumPress Releases
Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
2y ago
APGN
Apexigen to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
PremiumPress Releases
Apexigen to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
2y ago
APGN
Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
PremiumPress ReleasesApexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
2y ago
APGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >